liquid-biopsy-based tumor
monitoring. Beyond that,
pro-active gathering
of clinical history and
outcomes information
combined with the
molecular information
that Strand identifies
from its sequencing tests
can lead to powerful
insights and help inform
the creation of India
specific guidelines.
All this is enabled
by StrandOmics, our
proprietary platform
for interpretation and
reporting. StrandOmics
integrates knowledge from
all the public databases
of variant-phenotype
correlates along with
knowledge curated from
published literature using
text mining and expert
curation by highly skilled
senior scientists at Strand.
Over 6,000 clinical
samples have been taken
through the platform and
this has contributed to a
pooled database of Indian
(South Asian) ethnicity
genomes. As our tests are
being adopted as standard
of care in leading cancer
hospitals, we believe
that Strand can rapidly
build a clinical genomics
database at a scale which
could make India a
future leader in onco-
genomic medicine.
What would be the
top five priorities of
Strand Life Sciences
during 2017 and next
few years?
Strand Life Sciences will
continue to expand its
portfolio of products on
both the Bioinformatics
and Clinical Diagnostics
side. The science behind
both fields is constantly
evolving with new
research insights being
published every day, so
in order to keep up with
these advances and to stay
relevant for our customers
our products have to
evolve, too. Apart from
expansion, there is always
scope to enhance scientific
depth and accuracy as the
science and technology
progress and hence a
lot of our R&D efforts
will be focused in this
direction. On the clinical
diagnostics side, while we
get benchmarked against
the world’s best, we also
believe in the “Make
in India” mandate, in
particular, providing our
products at affordable
cost is a serious part of
our vision.
We plan to expand reach
by ensuring that our
product network is made
wider by reaching multi-
specialty doctors and
larger number of hospitals
in India. Strand beli eves
BIOVOICENEWS.COM
37